Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORION-PLAQUE inclisiran plaque progression study
2024-511126-31-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in non-obstructive coronary artery disease comparing Inclisiran plus maximally tolerated statin therapy with Placebo plus maximally tolerated statin therapy (2 arms). Primary endpoint: Percentage change from baseline to Month 24 in total coronary atheroma volume. Started Aug 2022; status: completed.
02
Drugs
inclisiran
03
Conditions
non-obstructive coronary artery disease
Beyond the preview
Go deeper on 2024-511126-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511126-31-00.